TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07722741: Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Sponsor: Geneos Therapeutics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,117,200

Rescue Site Savings

+$735,000

Unlock Full NCT07722741 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07722741 Rescue Dossier →